Key Takeaways
- Record FY24, anchored by Revlimid: Consolidated revenue and profits hit all-time highs, with Revlimid contributing a "good portion" of Q4 earnings alongside strong RoW performance.
- FY25 guided for >20% profit growth: Management expects top-line growth above 15-20% and profit growth comfortably above 20%, contingent on product mix holding and no major surprises.
- Pipeline is a bet on execution, not ideas: The Revlimid replacement strategy rests on converting 5-6 niche first-to-file opportunities (Semaglutide, Olaparib, etc.) into revenue, with management calling 2-3 successes in the next two years "a tremendous success."
- Capital allocation is at a fork: Natco is actively hunting for a large RoW acquisition to build a stable base business; if that fails, a buyback is on the table.
- What to watch next quarter: Whether the Crop Sciences business hits its reset growth trajectory after a ~Rs. 25-30 crore shortfall, and any concrete movement on the acquisition front.
The Revlimid Bridge & Replacement Pipeline
- Current contribution is material but opaque: Revlimid is a "good portion" of Q4 earnings, but management flatly refused to quantify its contribution or discuss pricing trajectory, calling it "strategic."
- The Teva arrangement has a tail: The profit-share arrangement for the U.S. market will continue beyond the January 2026 settlement date on "pretty much the same terms," extending the cash flow stream.
- The replacement portfolio is a known list: The pipeline includes Semaglutide (FTF), Wegovy (sole FTF in some circumstances), Olaparib, Yondelis, Trabectedin, and Carfilzomib, with Imbruvica dependent on a court case.
- Success is defined modestly: Management needs to build 2-3 more ideas in the next 2 years to reach 6-7 total for consistent generation; delivering even "1 to 1.5" first-to-files in that window would be "a great job."
- Launch timelines are unknowable from the outside: Settlements are bound by confidentiality and litigations are unresolved, so specific launch dates cannot be disclosed; they "will open up in the next few years."
Rajeev Nannapaneni: "I think it's not the lack of ideas. It's only about execution. I was just saying, right, if we pull off another 3 ideas in the next 2 years, we have done a great job."
Base Business & RoW Expansion
- RoW is the stability anchor: Brazil and Canada performed extremely well, with direct and subsidiary exports reaching nearly $25-26 million annually and the Canadian subsidiary nearing CAD 4 crore.
- Domestic formulation business reset: A one-time charge of roughly Rs. 90 crores hit the domestic segment due to distribution changes, but the underlying run rate remains at 95-100% with 14-15% growth expected from the Rs. 386 crore FY24 base.
- gCopaxone is steady but facing structural decline: With only two generics on the market, Mylan has done well, but the multiple sclerosis patient base is gradually shifting from injectors to oral formulations, causing a slight consumption decline.
- The acquisition thesis is about distribution, not molecules: Management sees Emerging Markets as "a lot like domestic," where local brands, a consistent distribution arm, and stability in earnings justify the search for a large RoW acquisition in the next couple of years.
Rajeev Nannapaneni: "Emerging Markets are very interesting, They are very consistent. They are a lot like domestic. I mean, there you have local brands and you have a sustainable business. You have a distribution arm, which is consistent and large and gives you stability in earnings."
Crop Sciences: A Reset, Not a Write-Off
- FY24 missed its target: The agri business fell Rs. 25-30 crores short of the Rs. 140-150 crore target because of a poor monsoon, product returns, and a deliberate decision to clean up stock rather than carry it forward.
- Pheromone adoption stalled on price: The product has not taken off as expected because cost of goods kept pricing high, and India's price-sensitive market resisted adoption despite appreciation for the product.
- CTPR combination is the bright spot: The combination product has done well, and management considers building a Rs. 100 crore brand business from scratch in 3-4 years a "laudable achievement."
- The ambition is intact: The internal target is to triple the business to Rs. 300 crores in the next 3 years, though it will take another 2-3 years for the business to get fully established.
Rajeev Nannapaneni: "I think we have done well with the CTPR combination. Pheromone has not taken off as well as we thought. I think it's a lot of appreciation for the product, but I think the pricing has been on the higher side because of the cost of goods being high."
Margins, Costs & Capital Allocation
- Margins are mix-dependent: Management stated that based on the current product mix holding up, margins are sustainable for the next year or two, but offered no tolerance band around that statement.
- The one-time charge had multiple components: The Rs. 90 crore hit included both the domestic distribution change and an API/agro intermediate write-down at a third-party site built for internal agrochemical launches.
- CAPEX is maintenance-plus, not transformational: Natco expects to spend Rs. 300-350 crores annually on maintenance CAPEX and expanding capacity at existing sites, with no new greenfield sites planned.
- The buyback is a Plan B: Management is "thinking about" a buyback but only if it cannot close a large enough acquisition; the decision will unfold through the year.
- Conservative guidance is a deliberate philosophy: Management prefers to "say less and do more," explicitly factoring in that "something will go wrong."
Rajeev Nannapaneni: "Say less, then you do more, people are happy with you. If you say more and you do less, everybody is unhappy with you. So, I think that's my way of looking at it."
Early-Stage Bets & Regulatory Overhang
- Cellogen is a small option on CAR-T: Natco made a modest investment in Cellogen for cell and gene therapy solutions, with an option to invest more depending on progress; management declined to give timelines, calling it "very early stage."
- One NCE is in the clinic: A new chemical entity is in Phase II in the U.S. for oral cancer, but management is refraining from giving guidance at this early stage.
- Kothur plant is under regulatory scanner: The facility is under scrutiny, though no further details were provided on the call.
- Rimegepant filing faces a crowd: Natco filed its migraine product but was one of 7 or 8 filers on day one, limiting the first-to-file opportunity.
- The next technology horizon is broad: Management is evaluating Oligopeptides, drug delivery systems, niche Para-IVs, and hard-to-do oncology products as areas for future investment.
Rajeev Nannapaneni: "Nothing is easy... I think we have proved ourselves consistently over the last decade that we can deliver these complex generics. And we have good execution capabilities. I think there's no doubt in that. We have a knack for finding these niches."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Profit growth | Greater than 20% growth for FY25 | FY25 |
| Top-line growth | More than 15% to 20% growth | FY25 |
| Earnings growth | About 20% comfortably, based on certain price erosion assumptions | FY25 |
| Domestic formulation growth | 14% to 15% growth from Rs. 386 crore FY24 base | FY25 |
| Crop Sciences target | Triple the business to Rs. 300 crores | Next 3 years |
| CAPEX | Rs. 300-350 crores per year for maintenance and expansion at existing sites | Ongoing |
| Revlimid profit share with Teva | Continue on pretty much the same terms beyond Jan '26 settlement date | Post-January 2026 |
| First-to-file execution target | Achieve 2-3 first-to-files with limited competition; even 1-1.5 is a great job | Next 2 years |
| RoW acquisition | Hoping to find a large acquisition to strengthen base business | Next couple of years |
| Buyback | Consider if unable to close a large acquisition | Decision during FY25 |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Consolidated total revenue (FY24) | ₹4,126.9 cr, +47% YoY vs ₹2,811.7 cr |
| Consolidated net profit (FY24) | ₹1,388.3 cr, +94% YoY vs ₹715.3 cr |
| Q4 PAT | ₹380 cr, after exceptional cost of ₹90 cr |
| One-time charge (domestic) | ₹90 cr, includes ₹35 cr domestic business model change and agro inventory hit |
| Domestic business annual sales (FY24) | ~₹386 cr, growing 8–10% |
| Base business PAT | ~₹350–400 cr (per management estimate) |
| Cash and investable liquid assets | ₹2,004 cr as of May 26, 2024; net cash position |
| Debt | ₹116 cr, comprising ₹40 cr EPC credit and ₹76 cr foreign discounting |
| Other income (Q4) | ₹42 cr, of which ~₹30 cr from interest on deposits |
| Brazil exports (annual) | $25–26 mn, direct plus subsidiary exports |
| Canada subsidiary profit | ~CAD 4 cr |
| Agri business revenue (FY24) | ~₹110–120 cr, fell short of ₹140–150 cr target by ₹25–30 cr |
| Agri business target (3-year) | ₹300 cr, internal target to triple |
| Annual CAPEX | ₹300–350 cr, maintenance and capacity expansion at existing sites |
| Employee count | ~5,000 excluding contractors, ~5,700–5,800 including contractors |
| Operating margin (FY24) | 43%, up from 33% in FY23 and 29% in FY21 |
| FY25 revenue growth guidance | >15–20% |
| FY25 earnings growth guidance | ~20% |